Arno Therapeutics extends expiration of 2012, 2013 placement warrants

Warrants now set to expire Jan. 31, 2015, extended from Dec. 31, 2014

By Devika Patel

Knoxville, Tenn., Dec. 31 – Arno Therapeutics, Inc. revised the terms of its series B and series E warrants on Dec. 30, according to an 8-K filed Wednesday with the Securities and Exchange Commission. The warrants, issued in 2012 and 2013, are exercisable for a total of about 19 million common shares.

The warrant expiration date for all warrants has been extended to Jan. 31, 2015, extended from Dec. 31, 2014.

Based in Parsippany, N.J., Arno is a clinical-stage biopharmaceutical company focused on developing oncology therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.